Last10K.com

Vanda Pharmaceuticals Inc. (VNDA) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Vanda Pharmaceuticals Inc.

CIK: 1347178 Ticker: VNDA

Exhibit 99.1

 

LOGO

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

 

   

Full year 2019 total revenues grew to $227.2 million, an 18% increase compared to 2018

 

   

Full year 2020 total revenues expected to be between $240 million and $260 million

 

   

Results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis reported today

WASHINGTON – February 25, 2020 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:

VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2019.

“We had another year of outstanding commercial growth,” said Mihael H. Polymeropoulos, M.D., Vanda’s President and CEO. “I have never been more excited about the opportunities ahead with our relentless focus on developing innovative therapies for patients in need.”

Key Financial Highlights

 

   

Total revenues were $60.9 million in the fourth quarter of 2019, a 15% increase compared to $53.0 million in the fourth quarter of 2018. Total revenues were $227.2 million for the full year 2019, an 18% increase compared $193.1 million for the full year 2018.

 

   

HETLIOZ® net product sales were $38.6 million in the fourth quarter of 2019, a 19% increase compared to $32.4 million in the fourth quarter of 2018. HETLIOZ® net product sales were $143.0 million for the full year 2019, a 23% increase compared to $115.8 million for the full year 2018.

 

   

Fanapt® net product sales were $22.3 million in the fourth quarter of 2019, an 8% increase compared to $20.6 million in the fourth quarter of 2018. Fanapt® net product sales were $84.2 million for the full year 2019, a 9% increase compared to $77.3 million for the full year 2018.

 

   

Cash, cash equivalents and marketable securities (Cash) were $312.1 million as of December 31, 2019, representing an increase to Cash of $54.8 million compared to December 31, 2018.

Key Product and Pipeline Highlights

Tradipitant

 

   

Results from the EPIONE study of tradipitant in the treatment of pruritus in atopic dermatitis were reported today. Vanda will reassess EPIONE 2 and determine next steps.

 

   

Enrollment in the Phase III study of tradipitant in gastroparesis (VP-VLY-686-3301) is ongoing.

 

   

Vanda expects to complete the Phase III program of tradipitant in motion sickness and file a New Drug Application with the U.S. Food and Drug Administration (FDA) in 2020.

 

   

Vanda continues to engage with the FDA over the requirement of a 9-month dog toxicity study.


The following information was filed by Vanda Pharmaceuticals Inc. (VNDA) on Tuesday, February 25, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Vanda Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vanda Pharmaceuticals Inc..

Continue

Assess how Vanda Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Vanda Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Legal
Financial
Revenue
Other
Filter Subcategory:
All
Shares
Expense
Cash Flow
Product
Debt
Income
Other
Inside Vanda Pharmaceuticals Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity
Consolidated Statements Of Comprehensive Income (Loss)
Consolidated Statements Of Operations
Accounts Payable And Accrued Liabilities
Accounts Payable And Accrued Liabilities (Detail)
Accounts Payable And Accrued Liabilities (Tables)
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Tables)
Accumulated Other Comprehensive Income - Additional Information (Detail)
Accumulated Other Comprehensive Income - Summary Of Accumulated Balances Related To Each Component Of Other Comprehensive Income (Loss) (Detail)
Business Organization And Presentation
Business Organization And Presentation (Detail)
Commitments And Contingencies
Commitments And Contingencies - Cftr Activators And Inhibitors - Additional Information (Detail)
Commitments And Contingencies - Fanapt - Additional Information (Detail)
Commitments And Contingencies - Hetlioz - Additional Information (Detail)
Commitments And Contingencies - Purchase Commitments (Detail)
Commitments And Contingencies - Tradipitant - Additional Information (Detail)
Earnings Per Share
Earnings Per Share (Detail)
Earnings Per Share (Tables)
Employee Benefit Plan
Employee Benefit Plan (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Assets Measured At Fair Value On Recurring Basis (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Components Of Deferred Tax Assets, Net And Related Valuation Allowance (Detail)
Income Taxes - Reconciliation Between Statutory Tax Rate And Effective Tax Rate (Detail)
Income Taxes - Summary Of Domestic And Foreign Components Of Income (Loss) Before Income Taxes (Details)
Income Taxes - Summary Of Gross Unrecognized Income Tax Benefits (Details)
Income Taxes - Summary Of Provision (Benefit) For Income Taxes (Detail)
Income Taxes - Valuation Allowance Activity On Deferred Tax Assets (Detail)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Fanapt - Additional Information (Detail)
Intangible Assets - Hetlioz - Additional Information (Detail)
Intangible Assets - Summary Of Amortization Expense (Detail)
Intangible Assets - Summary Of Future Intangible Asset Amortization (Detail)
Intangible Assets - Summary Of Intangible Assets (Detail)
Inventory
Inventory (Detail)
Inventory (Tables)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Lease Assets And Liabilities (Details)
Leases - Maturities (Details)
Leases - Maturities Under Asc 840 (Details)
Legal Matters
Marketable Securities
Marketable Securities (Tables)
Marketable Securities - Available-For-Sale Marketable Securities (Detail)
Property And Equipment
Property And Equipment (Tables)
Property And Equipment - Additional Information (Detail)
Property And Equipment - Property And Equipment-At Cost (Detail)
Public Offering Of Common Stock
Public Offering Of Common Stock (Details)
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited) (Detail)
Quarterly Financial Data (Unaudited) (Tables)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model For Stock Options Granted (Detail)
Stock-Based Compensation - Rsu - Additional Information (Detail)
Stock-Based Compensation - Stock Option - Additional Information (Detail)
Stock-Based Compensation - Summary Of Option Activity For 2006 Plan And The 2016 Plan (Detail)
Stock-Based Compensation - Summary Of Rsu Activity Plan (Detail)
Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Net Sales By Product (Detail)
Summary Of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents And Restricted Cash (Details)
Summary Of Significant Accounting Policies - Schedule Of Major Customers That Represented More Than 10% Of Accounts Receivable, Net (Detail)
Summary Of Significant Accounting Policies - Schedule Of Major Customers That Represented More Than 10% Of Total Revenues (Detail)
Summary Of Significant Accounting Policies - Summary Of Product Return Allowance (Detail)

Material Contracts, Statements, Certifications & more

Vanda Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits

Ticker: VNDA
CIK: 1347178
Form Type: 10-K Annual Report
Accession Number: 0001347178-20-000003
Submitted to the SEC: Wed Feb 26 2020 7:02:16 AM EST
Accepted by the SEC: Wed Feb 26 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/vnda/0001347178-20-000003.htm